ESMO Breast 2023 | KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs

Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses final analysis of the Phase III KEYNOTE-355 study (NCT02819518) in advanced triple-negative breast cancer (TNBC) patients. The study evaluated the efficacy of pembrolizumab (pembro) plus chemotherapy compared to placebo plus chemotherapy. It was found that pembro plus chemo significantly improved progression-free survival (PFS) and overall survival (OS) in patients with TNBC and a PD-L1 combined positive score (CPS) of ≥10. The analysis showed that patients who discontinued chemotherapy before pembro and those who experienced immune-mediated adverse events still demonstrated efficacy with pembro plus chemo. These results indicate the efficacy of pembro plus chemo in TNBC regardless of chemotherapy discontinuation or immune-mediated adverse events. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.